Neurocritical Care News

The most common neurological manifestations of COVID-19 for individuals living in Saudi Arabia were headache, changes in smell and taste, muscle pain, loss of consciousness and seizures, which were similar to global reports.

The FDA has granted fast track designation to Avidity Biosciences Inc. for its novel RNA therapeutic AOC 1020, an antibody oligonucleotide conjugate being studied for the treatment of facioscapulohumeral muscular dystrophy.

U.K.-based biotechnology company Pheno Therapeutics announced it has entered into an exclusive worldwide license agreement with Belgian-based biopharmaceutical company UCB to deliver new therapeutics for neurodegenerative disease.

Quantitative pupillometry may be a reliable method of assessing clinically intoxicated patients in EDs, per a study published in the Journal of the American College of Emergency Physicians Open.

Myrtelle Inc. announced updated findings of the open-label phase 1/2 clinical trial of its recombinant adeno-associated virus vector-based investigational gene therapy for Canavan disease, a fatal genetic disorder in children.

A team of three Ohio research companies has won a seat on an 8-year, $149 million indefinite delivery, indefinite quantity contract vehicle for the National Institute of Neurological Disorders and Stroke.

Treatment with nusinersen led to continued and improved motor function up to 5 years after initial dose in infants with spinal muscular atrophy, according to a poster presented at the International Scientific Congress on Spinal Muscular Atrophy.

The manufacturer of Leqembi announced it has submitted a supplemental Biologics License Application to the FDA to support the conversion of its recent accelerated approval to a traditional approval.

Quanterix Corp. announced the validation of a laboratory developed test to quantitatively measure neurofilament light chain in serum as an aid in the evaluation of those who may have neurodegenerative conditions.

Amyloid positron emission tomography scan changes were similar between individuals with autosomal dominant Alzheimer’s disease and those with Down syndrome, researchers reported in The Lancet Neurology.